COMMUNIQUÉS West-GlobeNewswire

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

03/10/2024 - 09:00

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors Enara Bio’s EDAPT® platform is [...]

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

03/10/2024 - 08:31

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated [...]

Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.

03/10/2024 - 08:00

CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical development programs of [...]

IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain

03/10/2024 - 07:00

A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium , October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]

IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU pour créer une chaîne de valeur complète pour l'Astate-211

03/10/2024 - 07:00

Une initiative de 16 millions d'euros pour établir l'autonomie stratégique de l'UE en matière de thérapies alpha contre le cancer Louvain-la-Neuve, Belgique, 3 octobre 2024 - IBA (Ion Beam Applications S.A., EURONEXT), [...]

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

03/10/2024 - 07:00

Saint Herblain (France), October 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will host an investor day at the Lotte New York Palace Hotel in New York, [...]

Valneva organise une journée investisseurs à New York le 10 octobre 2024

03/10/2024 - 07:00

Évènement en présentiel et retransmis en direct à 10h00 ET (16h00 CET) Saint Herblain (France), le 3 octobre 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’ [...]

The Pennant Group Announces Pricing of Public Offering of Common Stock

03/10/2024 - 02:34

EAGLE, Idaho, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG) (the “Company”) today announced the pricing of an underwritten public offering of 3,500,000 shares of its common stock at a public [...]

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

03/10/2024 - 02:20

– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) [...]

Oncocyte Signs Leading Transplant Centers in US and Germany

03/10/2024 - 00:41

GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volume Company clears first stage gate in clinical product development process and has submitted a Q-Sub to [...]

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

03/10/2024 - 00:35

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “ [...]

Monthly information on share capital and company voting rights

02/10/2024 - 22:30

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

02/10/2024 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 02 oct. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

02/10/2024 - 22:30

Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE [...]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/10/2024 - 22:30

SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

02/10/2024 - 22:28

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/10/2024 - 22:15

WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions

02/10/2024 - 22:15

AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio. [...]

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/10/2024 - 22:15

WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]